Literature DB >> 26227551

Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.

Chandrima Sinha1,2, Weiqiang Zhang2,3, Chang Suk Moon1, Marcelo Actis4, Sunitha Yarlagadda1, Kavisha Arora1, Koryse Woodroofe1, John P Clancy1, Songbai Lin1, Assem G Ziady1, Raymond Frizzell5, Naoaki Fujii4, Anjaparavanda P Naren6,7.   

Abstract

Cystic fibrosis (CF) is a lethal genetic disease caused by the loss or dysfunction of the CF transmembrane conductance regulator (CFTR) channel. F508del is the most prevalent mutation of the CFTR gene and encodes a protein defective in folding and processing. VX-809 has been reported to facilitate the folding and trafficking of F508del-CFTR and augment its channel function. The mechanism of action of VX-809 has been poorly understood. In this study, we sought to answer a fundamental question underlying the mechanism of VX-809: does it bind CFTR directly in order to exert its action? We synthesized two VX-809 derivatives, ALK-809 and SUL-809, that possess an alkyne group and retain the rescue capacity of VX-809. By using Cu(I) -catalyzed click chemistry, we provide evidence that the VX-809 derivatives bind CFTR directly in vitro and in cells. Our findings will contribute to the elucidation of the mechanism of action of CFTR correctors and the design of more potent therapeutics to combat CF.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CFTR correctors; VX-809; click chemistry; cystic fibrosis; protein expression

Mesh:

Substances:

Year:  2015        PMID: 26227551      PMCID: PMC4672727          DOI: 10.1002/cbic.201500123

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  28 in total

1.  Promising new era dawns for cystic fibrosis treatment.

Authors:  Zöe Corbyn
Journal:  Lancet       Date:  2012-04-21       Impact factor: 79.321

2.  A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy?

Authors:  Sunitha Yarlagadda; Weiqiang Zhang; Himabindu Penmatsa; Aixia Ren; Kavisha Arora; Anjaparavanda P Naren; Fatima Anmol I Khan; Catherine A Donnellan; Saumini Srinivasan; Dennis C Stokes; John C Kappes
Journal:  Am J Respir Crit Care Med       Date:  2012-10-01       Impact factor: 21.405

Review 3.  Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

Authors:  Rebecca S Pettit
Journal:  Ann Pharmacother       Date:  2012-06-26       Impact factor: 3.154

4.  Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a comparative study.

Authors:  Christen Besanceney-Webler; Hao Jiang; Tianqing Zheng; Lei Feng; David Soriano del Amo; Wei Wang; Liana M Klivansky; Florence L Marlow; Yi Liu; Peng Wu
Journal:  Angew Chem Int Ed Engl       Date:  2011-07-14       Impact factor: 15.336

5.  Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Authors:  Haihui Yu; Bill Burton; Chien-Jung Huang; Jennings Worley; Dong Cao; James P Johnson; Art Urrutia; John Joubran; Sheila Seepersaud; Katherine Sussky; Beth J Hoffman; Fredrick Van Goor
Journal:  J Cyst Fibros       Date:  2012-01-30       Impact factor: 5.482

6.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Authors:  J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan
Journal:  Thorax       Date:  2011-08-08       Impact factor: 9.139

7.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Jeffrey H Stack; Kimberly S Straley; Caroline J Decker; Mark Miller; Jason McCartney; Eric R Olson; Jeffrey J Wine; Ray A Frizzell; Melissa Ashlock; Paul A Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-05       Impact factor: 11.205

8.  Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.

Authors:  Michael B Donald; Kevin X Rodriguez; Hannah Shay; Puay-Wah Phuan; A S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem       Date:  2012-07-06       Impact factor: 3.641

Review 9.  Compartmentalization of cyclic nucleotide signaling: a question of when, where, and why?

Authors:  Kavisha Arora; Chandrima Sinha; Weiqiang Zhang; Aixia Ren; Chang Suk Moon; Sunitha Yarlagadda; Anjaparavanda P Naren
Journal:  Pflugers Arch       Date:  2013-04-19       Impact factor: 3.657

10.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein.

Authors:  Lihua He; Pradeep Kota; Andrei A Aleksandrov; Liying Cui; Tim Jensen; Nikolay V Dokholyan; John R Riordan
Journal:  FASEB J       Date:  2012-10-26       Impact factor: 5.191

View more
  10 in total

Review 1.  Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.

Authors:  Kevin G Chen; Pingyu Zhong; Wei Zheng; Jeffrey M Beekman
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

Review 2.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

3.  Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.

Authors:  Deborah M Cholon; Charles R Esther; Martina Gentzsch
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-04-22

4.  Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia.

Authors:  Dana C Borcherding; Matthew E Siefert; Songbai Lin; John Brewington; Hesham Sadek; John P Clancy; Scott M Plafker; Assem G Ziady
Journal:  J Clin Invest       Date:  2019-05-30       Impact factor: 14.808

5.  Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis.

Authors:  Miquéias Lopes-Pacheco; Inna Sabirzhanova; Daniele Rapino; Marcelo M Morales; William B Guggino; Liudmila Cebotaru
Journal:  Chembiochem       Date:  2016-02-16       Impact factor: 3.164

6.  Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.

Authors:  Nesrine Baatallah; Ahmad Elbahnsi; Isabelle Callebaut; Alexandre Hinzpeter; Jean-Paul Mornon; Benoit Chevalier; Iwona Pranke; Nathalie Servel; Renaud Zelli; Jean-Luc Décout; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Cell Mol Life Sci       Date:  2021-10-29       Impact factor: 9.261

Review 7.  One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Authors:  Marjolein M Ensinck; Marianne S Carlon
Journal:  Cells       Date:  2022-06-08       Impact factor: 7.666

Review 8.  Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.

Authors:  W Zhang; X Zhang; Y H Zhang; D C Strokes; A P Naren
Journal:  Drugs Today (Barc)       Date:  2016-04       Impact factor: 2.245

Review 9.  Hallmarks of therapeutic management of the cystic fibrosis functional landscape.

Authors:  Margarida D Amaral; William E Balch
Journal:  J Cyst Fibros       Date:  2015-10-29       Impact factor: 5.482

Review 10.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.